Cantor Fitzgerald analyst Louise Chen lowered her price target for Perrigo to $60 from $107, driven by multiple contraction, given increasing headwinds from macro factors. The analyst notes that competition for its OTC products in the U.S. and Europe could have a negative effect on the company's market share and pricing, weaker-than-expected allergy, cough and cold as well as flea and tick seasons could adversely affect sales, and manufacturing issues could adversely affect sales. Nonetheless, Chen reiterates an Overweight rating on the shares.

Perrigo announced that pharmaceutical company Esteve Healthcare has signed a binding offer to acquire Perrigo's HRA Pharma Rare Diseases business for a total consideration of up to EUR 275M, consisting of an upfront cash payment of EUR 190M and up to EUR 85M in potential earnout payments based on the Rare Diseases business achieving certain sales milestones. Following the information and consultation process with HRA Pharma Works Council in France, Perrigo would be able to exercise the put option granted by Esteve and enter into a definitive agreement with Esteve for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the third quarter of 2024, subject to the satisfaction of the HRA Works Council consultation and customary closing conditions, including receipt of regulatory approvals.